On the stock market since 2010, it operates in the world of health and science. It has 204 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 37% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $4.3M. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 19% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 23% a year on average.
Over the last 12 months, company executives reported 8 buys and 1 sell. Management buying with its own money is usually read as a good sign.
The stock sits at $0.41. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, GRUSF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GRUSF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.